Full history for every metric is available with a Kvantra account
Endymed Ltd (ENDY.TA)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 18 | 16 | 14 | 22 | 21 | 23 | 19 |
| Operating profit | $m | 1 | -2 | |||||
| Net profit | $m | 2 | 2 | 0 | 5 | 1 | 1 | -2 |
| EPS reported | $ | 0.04 | -0.13 | |||||
| Operating cashflow per share | $ | -0.05 | -0.05 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.05 | -0.05 | |||||
| Free cash flow | $m | -1 | -2 | |||||
| Net debt | $m | -10 | -7 | |||||
| Book value equity | $m | 15 | 13 | |||||
| Book value per share | $ | 1.11 | 0.96 | |||||
| Number of shares | m | 13.81 | 13.76 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 20.60 | - | |||||
| P/B LTM | x | 0.77 | 1.09 | |||||
| P/S LTM | x | 0.51 | 0.76 | |||||
| P/FCF LTM | x | -16.58 | -6.21 | |||||
| EV/EBITDA LTM | x | 2.11 | -5.01 | |||||
| EV/Sales LTM | x | 0.14 | 0.39 | |||||
| Earnings Yield LTM | % | 4.85% | 3.83% | |||||
| FCF Yield | % | -6.03% | -16.09% | |||||
| Quality | ||||||||
| ROE | % | 3.62% | 3.69% | |||||
| ROIC | % | 2.87% | 2.87% | |||||
| Operating margin | % | 4.05% | 4.05% | |||||
| Gross margin | % | 51.20% | 51.20% | |||||
| FCF/Sales | % | -3.09% | -3.09% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -34.26% | - | |||||
| Sales Growth YoY | % | +6.77% | -17.00% | |||||
| Net Income Growth YoY | % | -34.94% | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | -32.55% | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.55 | -2.03 | |||||
| Net Debt/EBITDA | x | -5.52 | -5.52 | |||||
| EBIT/Net interest | x | 25.61 | 25.61 | |||||
| Net debt/market cap | % | -83.29% | -48.36% | |||||
| Net debt/Equity | x | -0.64 | -0.53 | |||||
| Gross debt/equity | x | 0.08 | 0.09 | |||||
Company overview
Endymed Ltd is a medical technology company focused on the global design, development, and sale of energy-driven aesthetic treatment systems, catering to both professional practitioners and individual consumers. Its product offerings include the versatile EndyMed PRO, a platform capable of multiple applications. Another key product, PURE 2.0, provides professional-grade skin tightening, body contouring, and functional skin resurfacing. Furthermore, the firm leverages its proprietary 3DEEP radiofrequency technology to deliver a wide array of solutions for cosmetic enhancements, such as diminishing wrinkles, tightening skin, sculpting the body, improving texture, reducing cellulite and overall circumference, treating acne and related scarring, lessening stretch marks, performing RF microneedling, and fractional resurfacing. Established in 2007, the company is headquartered in Freehold, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Endymed Ltd (ENDY.TA)
Endymed Ltd is a medical technology company focused on the global design, development, and sale of energy-driven aesthetic treatment systems, catering to both professional practitioners and individual consumers. Its product offerings include the versatile EndyMed PRO, a platform capable of multiple applications. Another key product, PURE 2.0, provides professional-grade skin tightening, body contouring, and functional skin resurfacing. Furthermore, the firm leverages its proprietary 3DEEP radiofrequency technology to deliver a wide array of solutions for cosmetic enhancements, such as diminishing wrinkles, tightening skin, sculpting the body, improving texture, reducing cellulite and overall circumference, treating acne and related scarring, lessening stretch marks, performing RF microneedling, and fractional resurfacing. Established in 2007, the company is headquartered in Freehold, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free